Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2000

View Archived Issues

Company Profile: ProlX Pharmaceuticals

Millennium to acquire Cambridge Discovery Chemistry

Pharmacokinetics and pharmacodynamics of selective ETA antagonist examined in humans

Schering-Plough enters asthma collaboration with Texas Biotechnology

Methods of differentiating response to INN-00835 and placebo described at CINP congress

Propranolol may improve disruptive agitation in AD without serious cardiovascular effects

Cymserine and analogues, potent and selective BChE inhibitors with potential in AD

Neotrofin as a novel approach to AD discussed at World Alzheimer Congress

Virax and IDT receive funding from U.S. NIH to develop HIV vaccines

NIH accelerates development of HIV vaccines

[18F]-L-829165: a promising PET tracer for the brain NK1 receptor

AlphaOne enters agreement with Dana-Farber for tumor suppressor gene

Biological characteristics of A-176120, a potent FPP mimetic with promise as a cancer therapeutic

Antisense collaboration established by Lorus Therapeutics and AVI BioPharma

PathoGenesis commences phase I trial of AeroDose TOBI

Murine and humanized monoclonal antibodies against alphav integrin receptors

Synthesis, activity and use of new gabapentin-related compounds

Novo Nordisk presents new heterocyclic inhibitors of factor VIIa-TF activity

New Yissum compounds useful against oxidative stress or free radical injury

Tetracycline derivatives with broad indications reported by CollaGenex

Novel cathepsin K inhibitors and their use in bone disorders patented

Broad-spectrum antibacterial compounds emerge from Daiichi R&D

UT researchers patent dibenzofluorene derivatives with cytotoxic activity

New series under development at Glaxo Wellcome inhibits hepatic ApoB-100 production

T-20 phase II results highlighted at AIDS Conference

Genta begins follow-up studies of Genasense combination therapy for prostate cancer

CV Therapeutics and Fujisawa form CVT-3146 collaboration